Key result
Left atrial appendage closure is argued to warrant a stronger guideline recommendation for stroke prevention in atrial fibrillation patients who are unable to take oral anticoagulants.
Why the study?
Should left atrial appendage closure receive a stronger guideline recommendation for stroke prevention in atrial fibrillation patients who have contraindications to oral anticoagulants?
Should left atrial appendage closure receive a stronger guideline recommendation for stroke prevention in atrial fibrillation patients who have contraindications to oral anticoagulants?
Answers are grounded in this paper and cite their sources.
Guidelines may need to leap ahead of absolute RCT evidence by issuing stronger recommendations for LAAC in patients unable to tolerate oral anticoagulation.
Atrial fibrillation (AF) is associated with life-threatening thromboembolism. Most emboli stem from thrombosis in the left atrial appendage (LAA). The current treatment of choice is oral anticoagulants (OACs), but a small proportion of patients cannot take OACs predominantly because of the so-called unacceptable bleeding risks. However, many who initially accept OACs subsequently stop therapy or reduce the OAC treatment to a potentially non-effective dose leaving them exposed to thromboembolic risk. A relatively simple alternative therapy involves the catheter-based insertion of a LAA closure (LAAC) device to prevent thromboembolism from the LAA. There is a considerable evidence base for this therapy consisting of clinical trials and observational data which suggests comparable therapeutic efficacy with a possible small excess of ischaemic strokes. Although LAAC has been very closely examined by regulators and approved for market release, guidelines from most professional societies give only weak recommendations for use of this device which may be the only known effective therapy available to some at-risk AF patients. Guidance materials from the same societies more enthusiastically endorse LAAC. Clinical practice is running well ahead of the guidelines because equipoise has been lost by physicians faced with patients for whom they have no other effective therapy. Guideline writers are correct in providing recommendations which are less strong for LAAC than for OACs, for those who are able and willing to take OAC treatment, but for those who are not, a stronger recommendation is needed. But, should the guidelines lag behind or leap ahead of the available evidence?
No takes yet. Share an insight, caveat, or question.
A. John Camm (2023) conducted an editorial in Atrial fibrillation (AF). Left atrial appendage closure (LAAC) vs. Oral anticoagulants (OACs) was evaluated. Left atrial appendage closure is argued to warrant a stronger guideline recommendation for stroke prevention in atrial fibrillation patients who are unable to take oral anticoagulants.
Synapse has enriched 10 related papers. Consider them for comparative context: